ClinicalTrials.gg
RecruitingNCT07943143HRCCUpdated Nov 17, 2026

Histotripsy for Renal Cell Carcinoma

An interventional study of HistoSonics® Edison System (US) in Localised or Metastatic Renal Cell Carcinoma, sponsored by The University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by The University of Hong Kong · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Carcinoma, Renal Cell with a site in Hong Kong — 3 open to participants now, 9 under way, 6 of them phase 3. Carcinoma, Renal Cell · Hong Kong.

Planned enrollment
19th of 19
15 · median 317
Started
2026
the only one that year
No phase
3 of 20
2 open now
Registered
20th of 20
by date

Among the 20 studies in Carcinoma, Renal Cell with a site in Hong Kong, this one is the 19th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2026, is one of 3 with no phase, and was the 20th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

3 of the 20 studies in Carcinoma, Renal Cell with a site in Hong Kong are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Hong Kong have not opened yet or have stopped. Only those recruiting at a site in Hong Kong →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Carcinoma, Renal Cell with a site in Hong Kong, or all of them as a file.
02

Study summary

The project will be a pilot study in localised or metastatic renal cell carcinoma, assessing safety, local control, and exploratory immune endpoints. Outcomes from this work will inform rational combinations with targeted agents and immune checkpoint blockade and may define a new, image-guided, non-invasive modality for renal cell carcinoma. If successful, histotripsy could become a new non-thermal, local therapy for renal cell carcinoma with dual benefits of debulking and immune activation achieving strong clinical and scientific impact.

Read the detailed description

Study Design and Methodology

This study will enrol 15 patients with localised or metastatic renal cell carcinoma. Patients will be identified from clinic, and undergo a comprehensive evaluation, including imaging studies and laboratory tests, to confirm the diagnosis and assess their eligibility for histotripsy.

Procedure

Histotripsy will be performed by dedicated team of oncologist, urologist and radiologist who have undergone accredited training on Histotripsy aiming to achieve the best clinical outcomes and ensure patient safety. Patients are typically placed under general anaesthesia (GA) or monitored anaesthesia care (MAC) with real-time monitoring. The component of the Histotripsy machine that generates sound waves is positioned within a soft, flexible membrane filled with specially treated water, which rests on the patient's abdomen and facilitates the transmission of sound waves to the targeted tissue. The procedure will be delivered in a single session or multiple sessions by ultrasound, depending on the size and location of tumours.

Assessment

Patients will be invited to complete a questionnaire for pain score assessment before and after histotripsy.

Blood samples will be collected for clinical evaluation and laboratory tests at baseline, followed by 1-day, 30-day, 60-day, and 90-day after histotripsy, aligned with existing feasibility and trial schedules. Blood tests and cellular analysis such as complete blood profile, liver and renal function tests, tumour markers, immune markers and biomarkers etc. will be performed each time. Patients will be asked for consent for 15ml blood collection for the cellular analysis.

Serial post-histotripsy imaging (CT/MRI) will also be arranged. Imaging within 36-hour after histotripsy will be proceeded to confirm the ablation zone and assess complications. Post-procedure imaging at 1-, 3-, and 6-month will help to capture the sustainability of treatment effect, then per standard of care thereafter.

Admission and follow-up

Similar to other minimal invasive treatments, patients will be admitted one day prior, or on the day of procedure. After the procedure of histotripsy, patients may experience some discomfort in the treated area, but patients can often return to normal activities quickly. They could be discharged in few hours, or the next day after procedure depending on clinical conditions.

After discharge, follow-up consultations and assessments such as regular imaging and blood tests will be arranged accordingly.

Potential risk and discomfort

Blood drawn for laboratory tests can cause bruising at or near the site where the needle enters the vein and thus increase the risk of infection. Risks related to imaging scans will be explained prior to the procedures by the related doctors or medical professionals.

Procedure risk related to Histotripsy includes skin erythema or superficial burn injury, infection, bleeding, renal dysfunction, and abdominal wall injury or burn. Adverse post treatment event includes bleeding, infection, damage to surrounding structures etc. The medical team will monitor closely and response promptly.

Short-term effects

  • Mild pain or soreness that usually responds to oral pain medication
  • Low-grade fever and flu-like symptoms that typically resolve within 48 hours
  • Temporary skin redness at the treatment site
  • Mild abdominal discomfort
  • Temporary changes in renal function tests
  • Possible nausea or fatigue
  • Transient haematuria

Potential serious complications

  • Temporary decrease in kidney function
  • Potential damage to surrounding organs (liver, lung, bowel, or stomach)
  • Severe pain
  • Need for extended hospital stay or additional treatment for serious complications
  • Skin ulcer / necrosis requiring interventions
  • Vascular thrombosis / dissection

Long-term complications

  • Currently, there is no known long-term side effects from Histotripsy treatment. Ongoing research aims to evaluate the long-term outcomes.

In the event of complications arising from the study treatment, patients will be treated accordingly or referred for standard treatment and care.

Statistical analysis

Analysis will be performed for the 15 participants recruited, with basic demography (age, sex, medical history etc.), clinical evaluation, laboratory tests, imaging, treatment outcome with associated complication.

DATA AND BIOLOGICAL SAMPLES HANDLING

Patients will be invited to register on the Histotripsy (HistoSonics○R) Registry in Gleneagles Hospital Hong Kong for data collection. Collected personal and study data will be anonymised and stored in a password protected, encrypted database with the principal investigator and delegated staff in the long run. The principal investigator will be responsible for the safekeeping. Only investigators and delegated staff can have right to gain access to the data. All collected data and biological samples will be stored permanently for future review in histotripsy related research. Unused biological samples will be destroyed and discarded upon request, however, the results will remain a part of the overall research data if part of the sample has been proceeded.

Consent

Written voluntary consents will be obtained after full explanation of the study to patients before agreement of the histotripsy procedure.

Conflicts of interests

All investigators and funding bodies have no financial interests in the study.

Research ethics

The study will be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with ICH/Good Clinical Practice, and applicable regulatory requirements Patient data protection.

03

Conditions studied

  • Localised or Metastatic Renal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old
  • Fit for general anaesthesia
  • confirmed renal cell carcinoma; radiological diagnosis acceptable if is not feasible
  • With or without distant
  • Performance Status (ECOG PS) grade 0-2
  • Tumour visible and targetable by ultrasound with acceptable acoustic windows
  • Adequate hematologic, hepatic, and renal function ( ≥45mL/min, ≤14 days prior to the planned index procedure date).

Exclusion criteria

Exclusion Criteria:

  • Refusal to take part in clinical trial
  • Not fit for general anaesthesia
  • Poor general condition with limited
  • Uncontrolled coagulopathy
  • The treatment of the tumour will not allow for an adequate margin as determined by the investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Patients receiving Histotripsy procedure for renal cell cancer using the HistoSonics® Edison System

    Device: HistoSonics® Edison System (US)

Interventions

  • DeviceHistoSonics® Edison System (US)

    Patients with be admitted to Gleneages Hospital for histotripsy procedure. Pre-produce anaestetic assessment will occur and patients will be treated under general anasestetic with jet ventilation. Patient will be positioned in the left or right lateral position and a water tank will be placed over the patient's loin area. The histotripsy ultrasound and treatment head will be placed inside the water tank and image-guided histotripsy ablation of the kidney tumor will be performed. The expected length of hospital stay is 1 day after operation. Patient will undergo follow up with regular imaging up to 6 months.

06

What researchers measure

Primary outcomes

  1. To assess efficacy

    Successful treatment percentage at 90 days on MRI/CT post-procedure

    Time frame: 90 days post procedure

  2. To assess treatment safety

    Freedom from index procedure related major complications, defined by Clavien-Dindo Classification Grade 3 or higher

    Time frame: At 30 days

Secondary outcomes

  1. Pain score assessment before and after histotripsy

    Time frame: At baseline (after inpatient admission and before histotripsy) and day 2 (before discharge of patient) on a 11-point scale Numeric Pain Rating Scale (NPRS).

07

Study locations

1 of 1 sites recruiting
  • Gleneagles Hospital Hong Kong
    Hong Kong, Hong Kong
    Recruiting
    • Professor Matthew Kin-liang CHIU, PhD · Contactmklc2@hku.hk · +852 22554352
    • Wing Hang Vince Lau, MBBS, FHKCR, FHKAM · Sub investigator
    • Chi-Yan Albert Chan, MBBS, MS, FRCSEd, FCSHK, FHKAM · Sub investigator
    • Justin Christopher Ng, MBBChBAO, LMCHK, MMED, FRCR · Sub investigator
    • Pei Wayne Lam, MBBS, LMCHK, FRCSed, FCSHK · Sub investigator
    • Cho Wing Bryan Li, MBBS, MRCP, FHKCP, FHKAM · Sub investigator
    • Shung Lai John Leung, MBBS, FRCSEd, FCSHK, FHKAM · Sub investigator
    • Lok Hei Clarence Leung, MBChB, FRCSEd, FCSHK, FHKAM · Sub investigator
    • Hin Kay John Ngan, MBBS, FHKCS, FHKAM, FRCSE · Sub investigator
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Oct 2028, 24 months after the start.

Of 119 non-industry interventional studies with no phase under Carcinoma, Renal Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 114. This study's planned 24 months is below that.

Counting every sponsor, half of 126 studies reached it within 45 months; a quarter within 22 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2026
First posted
Nov 17, 2026
StartActual
Oct 13, 2026
Primary completionEst.
Oct 30, 2028
CompletionEst.
Oct 30, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943143
Collaborators
Gleneagles Hospital
Responsible party
Matthew Kin Liang Chiu (Clinical Assistant Professor, The University of Hong Kong) — Principal investigator
First posted
Nov 17, 2026
Start date
Oct 13, 2026
Primary completion
Oct 30, 2028 (estimated)
Completion
Oct 30, 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

Professor Matthew Kin-liang CHIU, PhD
Contact
mklc2@hku.hk
+852 22554352

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion